Oncology Drug Insights by OmicsX
No Result
View All Result
  • Login
  • Register
PRICING
SUBSCRIBE
No Result
View All Result
Oncology Drug Insights by OmicsX
No Result
View All Result
Home Big Pharma

Takeda Oncology-
Drug Pipeline Insights – June 2021

Oncology New Molecules Development Strategy

Team OmicsX by Team OmicsX
May 30, 2022
in Big Pharma, Onco Pipeline Insights, Oncology
505
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

Takeda Oncology (Millennium Pharmaceuticals, Inc) is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, developing therapies for the treatment of cancer.
In May 2008, Millennium was acquired by Takeda Pharmaceutical for $8.8 billion USD and is operating as an independent wholly owned subsidiary of Takeda.

Global Oncology Intelligence Global Oncology Intelligence
Jump to section

1. Takeda Oncology Major Oncology Drug Approvals

  • 1. Takeda Oncology Major Oncology Drug Approvals
  • 2. Takeda Oncology Active Clinical Stage Oncology Pipeline (10 Active Molecules)
  • In Dec 2020, the US FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, Relugolix, (ORGOVYX, Myovant Sciences, Inc.) for adult patients with advanced prostate cancer.
  • Earlier in 2016, Myovant Sciences Ltd. was launched through a strategic partnership between Roivant Sciences and Takeda, with Takeda granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries) to relugolix (TAK-385).
  • In May 2020, the US FDA approved brigatinib (ALUNBRIG®) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Brigatinib is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity.
  • In July 2020, U.S. FDA granted Breakthrough Therapy Designation to Pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS).
  • In Apr 2020, U.S. FDA granted Breakthrough Therapy Designation to Mobocertinib (TAK-788) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
  • In Nov 2015, US FDA approved Ixazomib (Ninlaro) for the treatment of multiple myeloma, in combination with other drugs.
  • In 2011, Brentuximab vedotin/Adcetris™, was approved by FDA for Anaplastic Large Cell Lymphoma and hodgkin’s lymphoma.
  • In 2009, Mepact® was approved in Europe for osteosarcoma. It was denied approval by US FDA in 2007 due to lack of clinical data.
  • In May 2003, Bortezomib/Velcade® was approved by FDA for multiple myeloma and in Dec 2006 for mantle cell lymphoma, who have received at least one prior therapy.
  • Bortezomib/Velcade® was developed by Millennium in collaboration with Johnson & Johnson Pharmaceutical.
Jump to section

1. Takeda Oncology Major Oncology Drug Approvals

  • 1. Takeda Oncology Major Oncology Drug Approvals
  • 2. Takeda Oncology Active Clinical Stage Oncology Pipeline (10 Active Molecules)
Page 1 of 2
Previous 12 Next
Previous Post

Boehringer Ingelheim GmbH – Oncology Drug Pipeline Insights – June 2021

Next Post

Approved Oncology Targeting Small Molecule Kinase Inhibitors

Next Post
Approved Oncology Targeting Small Molecule Kinase Inhibitors

Approved Oncology Targeting Small Molecule Kinase Inhibitors

Developed by OmicsX. The entirety of this site is protected by copyright © 2025 HH BioTechnologies Private Ltd.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result

Developed by OmicsX. The entirety of this site is protected by copyright © 2025 HH BioTechnologies Private Ltd.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?